

1 **Article**

2

3 **Comparative Effectiveness of Remineralization Agents on**  
4 **Attachment-Associated Enamel Demineralization in Clear Aligner**  
5 **Patients: A 6-Month DIAGNOdent-Based Controlled Clinical Trial**

6

7 Hasan Yasin Ünal 1, Banu Kılıç 2,\*, Evrim Eligüzeloğlu Dalkılıç 3

8

9 1 Department of Orthodontics, Institute of Health Sciences, Bezmialem

10 Vakif University,

11 Fatih, Istanbul 34093, Turkey; hasanyasinunal@hotmail.com;

12 <https://orcid.org/0009-0001-6486-7821>

13

14 2 Department of Orthodontics, Faculty of Dentistry, Bezmialem Vakif

15 University,

16 Fatih, Istanbul 34093, Turkey; bkilic@bezmialem.edu.tr;

17 <https://orcid.org/0000-0002-9207-4490>

18

19 3 Department of Restorative Dentistry, Faculty of Dentistry, Bezmialem

20 Vakif University,

21 Fatih, Istanbul 34093, Turkey; edalkilic@bezmialem.edu.tr;

22 <https://orcid.org/0000-0002-1075-9278>

23

24 \* Correspondence: bkilic@bezmialem.edu.tr; Tel.: +90-532-243-2756

25

26 Word Count:

27 Abstract: 257 words

28 Main Text: 4595

29 Number of Tables: 2

30 Number of Figures: 4

31 Additional Files: 0

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

ARTICLE IN PRESS

51

52

53

54 **ABSTRACT**

55

56 **Background/ Objectives:** Clear aligner attachments increase the risk of  
57 white spot lesions (WSL), with a 35.5% incidence in adolescents. The  
58 number of anterior attachments is an independent risk factor  
59 (OR=2.192). Despite 17 million patients treated worldwide, no study has  
60 quantitatively assessed demineralization around attachment margins. To  
61 compare the effectiveness of CPP-ACP, nano-hydroxyapatite (nHAp), and  
62 fluoride varnish versus a control for attachment-associated  
63 demineralization using DIAGNOdent monitoring.

64 **Methods:** This prospective controlled clinical trial evaluated 52 patients;  
65 45 were enrolled, and 40 completed after five pre-baseline withdrawals.  
66 Participants were allocated to four groups (n=10 each): Group A (control,  
67 fluoride toothpaste), Group B (CPP-ACP daily), Group C (nHAp  
68 professional + home gel), and Group D (fluoride varnish quarterly).  
69 DIAGNOdent measurements were taken around attachments at baseline,  
70 1, 3, and 6 months. Linear mixed-effects models analyzed group  
71 differences ( $p < 0.05$ ).

72 **Results:** All 40 participants completed the 6-month study (100%  
73 retention). Baseline values were comparable ( $p = 0.48$ ). Mean  
74 DIAGNOdent changes at 6 months were: Control +4.35 [95%CI: 3.77-

75 4.93], CPP-ACP  $-4.02$  [ $-4.47$  to  $-3.56$ ], nHAp  $-5.36$  [ $-5.99$  to  $-4.72$ ],  
76 Fluoride  $-4.45$  [ $-4.78$  to  $-4.11$ ]. The main group effect was significant  
77 ( $p < 0.001$ ;  $\eta^2 p = 0.974$ ). All treatments outperformed the control  
78 ( $p < 0.001$ ). nHAp showed the greatest reduction, superior to CPP-ACP  
79 ( $p < 0.001$ ) and fluoride ( $p = 0.019$ ). Fluoride exhibited a biphasic pattern.

80 **Conclusions:** All remineralization protocols significantly reduced  
81 demineralization versus control, with nHAp demonstrating the highest  
82 efficacy. Early preventive intervention and regular monitoring are  
83 recommended in attachment-bearing patients. Larger randomized trials  
84 are warranted.

85 **Trial registration:** ClinicalTrials.gov NCT07229105. Registered 13  
86 November 2025. Retrospectively registered.

87 **Keywords:** Clear aligners; Orthodontic attachments; White spot lesions;  
88 DIAGNOdent; Nano-hydroxyapatite

89 **Word count:** 258 words

90

## 91 **1. Introduction**

92

93 White spot lesions (WSLs) are the most prevalent iatrogenic complication  
94 of orthodontic treatment, affecting 2-97% of patients, depending on the  
95 assessment method and population studied[1, 2]. These incipient carious  
96 lesions, characterized by subsurface enamel demineralization with an  
97 intact surface layer[3], can develop within four weeks of plaque  
98 accumulation and progress to cavitation if left untreated[4]. Recent

99 evidence from Liu et al. reveals a striking 35.5% WSL incidence in clear  
100 aligner-treated adolescents, with the number of anterior attachments  
101 emerging as an independent risk factor (OR = 2.192, 95% CI: 1.158-  
102 3.782)[5].

103

104 Clear aligner therapy, utilized in over 17 million patients globally,  
105 employs composite resin attachments to facilitate complex movements[6].  
106 These attachments create plaque-retentive areas at the enamel-composite  
107 interface, where conventional hygiene measures prove insufficient[7, 8].  
108 The attachment-enamel margin presents unique challenges, such as  
109 altered surface topography, potential microleakage, and disrupted  
110 salivary clearance patterns[9]. Despite the widespread use of  
111 attachments, no clinical studies have specifically monitored  
112 demineralization at high-risk sites.

113

114 The relationship between clear aligners and WSL development remains  
115 poorly understood, despite growing clinical concerns. Systematic reviews  
116 have revealed conflicting evidence, with one noting that "clear aligners  
117 were associated with low WSL risk, but there is limited evidence of a  
118 protective effect" compared to fixed appliances[2, 10]. A recent scoping  
119 review found that "among five included studies, only one reported WSLs  
120 and showed no significant difference versus fixed appliances"  
121 underscoring the paucity of high-quality evidence[8]. The economic  
122 implications are substantial, with treatment and retreatment of WSLs

123 potentially costing up to €2,332 per patient[11], contributing to the global  
124 dental disease burden of US\$298 billion annually[12].

125

126 Alternative remineralization technologies have emerged to address the  
127 limitations of fluoride monotherapies. Calcium-phosphate technologies,  
128 particularly casein phosphopeptide-amorphous calcium phosphate (CPP-  
129 ACP), have been studied extensively. While some policy reviews note  
130 protocol-dependent effectiveness, a comprehensive 2025 systematic  
131 review confirmed that CPP-ACP demonstrates a statistically significant  
132 effect on the prevention and regression of white spot lesions compared to  
133 placebo or standard care[13]. Nanohydroxyapatite (nHAp) has emerged  
134 as a key biomimetic agent. A 2024 systematic review focusing on  
135 hydroxyapatite products confirmed their promising and comparable  
136 efficacy in enamel remineralization[14]. This aligns with a randomized  
137 controlled trial showing that "the nHAp group had higher  
138 remineralization ability than CPP-ACP at 1 month using DIAGNOdent  
139 measurements"[15].

140

141 Given the established risk of attachment-associated demineralization and  
142 the lack of evidence-based prevention protocols, this study aimed to  
143 compare the effectiveness of three remineralization strategies—CPP-ACP,  
144 nano-hydroxyapatite, and professional fluoride varnish—versus standard  
145 care in preventing enamel demineralization around clear aligner  
146 attachments using quantitative DIAGNOdent monitoring over six months.  
147 We hypothesized that there would be no significant difference (null

148 hypothesis,  $H_0$ ) in attachment-associated demineralization changes  
149 among CPP-ACP, nano-hydroxyapatite, fluoride varnish, and control  
150 groups as measured by DIAGNOdent over a 6-month period.

151

## 152 **2.Materials And Methods**

153

### 154 **Study Design and Setting**

155

156 This prospective controlled clinical trial was conducted at Bezmialem  
157 Vakif University Dentistry Faculty Orthodontic Clinic from August 2024 to  
158 March 2025. The study protocol was approved by the Institutional Review  
159 Board (Protocol No: 09/15, date: 22/05/2024). All participants provided  
160 written informed consent, and parental consent was obtained from  
161 patients aged 16-18 years. This study followed the STROBE  
162 guidelines[16], adapted for the reporting of controlled clinical trials.

163

### 164 **Sample Size and Recruitment**

165

166 This was an exploratory study using a convenience sample. No formal a  
167 priori sample-size calculation was performed. A total of 52 patients  
168 currently undergoing clear aligner therapy were assessed for eligibility  
169 between August and September 2024. Seven patients were excluded: two  
170 with systemic diseases, two who started medications affecting salivary  
171 flow, and three who declined participation. The remaining 45 patients

172 provided written informed consent and were allocated to the four  
173 treatment groups.

174  
175 Before the baseline measurements, five patients withdrew from the study.  
176 In Group B (CPP-ACP), two patients withdrew: one due to intolerance to  
177 sweet products with nausea during trial application and another due to  
178 concerns about potential allergic reactions given the dairy-based  
179 composition. In Group C (nHAp), one patient withdrew due to family  
180 relocation. In Group D (fluoride varnish), 2 patients withdrew their  
181 inability to attend regular clinical appointments. No withdrawals  
182 occurred in Group A (control). This resulted in 40 patients (n=10 per  
183 group) undergoing baseline DIAGNOdent measurements, all completed  
184 the 6-month protocol (100% post-baseline retention).

185

### 186 **Eligibility Criteria**

187

### 188 **Inclusion Criteria:**

189

- 190 - Age 16-45 years
- 191 - Active clear aligner treatment with minimum 6 months remaining
- 192 - Presence of  $\geq 10$  attachments on anterior teeth and premolars
- 193 - Good general health
- 194 - Commitment to prescribed aligner wear (20-22 hours/day)

195

### 196 **Exclusion Criteria:**

197

198 - Active carious lesions

199 - Periodontal disease

200 - Fluorosis or enamel hypoplasia

201 - Current fluoride supplement use beyond standard toothpaste

202 - Pregnancy or lactation

203 - Systemic conditions affecting salivary flow

204

## 205 **Group Allocation and Interventions**

206

### 207 **Group A: Control (n=10)**

208

209 The participants used standard fluoride toothpaste (1450 ppm) twice  
210 daily, with no additional remineralization protocol.

211

### 212 **Group B: Casein Phosphopeptide-Amorphous Calcium Phosphate** 213 **(n=10)**

214

215 In addition to the standard fluoride toothpaste, participants applied GC  
216 Tooth Mousse (GC Corporation, Tokyo, Japan) to their clear aligners once  
217 daily. The protocol involved:

218

219 - Dispensing a pea-sized amount of mousse into each aligner

220 - Wearing the aligner with mousse for 15 minutes

221 - No rinsing for 30 minutes post-application

222 - Application performed before bedtime

223

224 **Group C: Nano-Hydroxyapatite (n=10)**

225

226 This group received a combined and intensive protocol designed to  
227 maximize nano-hydroxyapatite exposure. It involved in-office applications  
228 of a nano-hydroxyapatite mineral gel (5% nHAp; BioWhiten ProOffice  
229 NanoCare Nano-Hydroxyapatite Mineral Jel, BiODENT MEDICAL,  
230 Istanbul, Turkey) performed by the examiner at baseline (T0), 1 month  
231 (T1), and 3 months (T2). This professional application was complemented  
232 by an at-home regimen consisting of daily application of a different nHAp  
233 dental care gel (1% nHAp; Biowhiten Nanocare nHAp Diş Bakım Jeli,  
234 BiODENT MEDICAL, Istanbul, Turkey), which participants squeezed into  
235 their aligners each night before sleeping (or for a minimum of 15 minutes  
236 if applied during the day). For routine daily brushing, participants in all  
237 four groups, including Group C, were provided with and instructed to  
238 exclusively use a standard fluoride toothpaste containing 1450 ppm  
239 fluoride.

240

241 **Group D: Professional Fluoride Varnish (n=10)**

242

243 The participants maintained the standard fluoride toothpaste use plus

244

245 - Professional application of 5% sodium fluoride varnish (ProShield  
246 varnish, PRESIDENT DENTAL GmbH, Allershausen, Germany) at baseline  
247 and 3 months

248 - Varnish applied to all tooth surfaces, with special attention to  
249 attachment margins

250 - 1 minute contact time before removal[17]

251 - No eating/drinking for 2 hours post-application

252

### 253 **Standardized Oral Hygiene Protocol**

254

255 For routine daily brushing (e.g., twice daily), participants in all four  
256 groups, including Group C, were provided with and instructed to  
257 exclusively use a standard fluoride toothpaste containing 1450 ppm  
258 fluoride. No other remineralizing toothpaste was permitted during the  
259 study period.

260

### 261 **DIAGNOdent Measurement Protocol**

262

### 263 **Calibration and Standardization**

264

265 The DIAGNOdent pen (KaVo, Biberach, Germany) was calibrated before  
266 each measurement session according to the manufacturer's instructions  
267 using a ceramic standard[18]. A single calibrated examiner performed all  
268 measurements to ensure consistency. Intra-examiner reliability was  
269 assessed using intraclass correlation coefficient (ICC) with two-way

270 mixed model, absolute agreement, calculated from 30 repeated  
271 measurements at 10 randomly selected attachment sites (ICC = 0.85,  
272 95% CI: 0.79-0.91).

273

### 274 **Measurement Technique**

275

276 A standardized measurement protocol was employed for all DIAGNOdent  
277 assessments. Teeth were air-dried for 5 seconds prior to measurement,  
278 and the probe tip was positioned perpendicular to the enamel surface to  
279 ensure consistent readings. Four measurements were obtained per  
280 attachment site at the mesial, distal, gingival, and occlusal margins.  
281 Three measurement passes were performed at each site, with the  
282 maximum value recorded to represent the most advanced  
283 demineralization present. Measurements were conducted at four  
284 timepoints: baseline (T0), 1 month (T1), 3 months (T2), and 6 months  
285 (T3).

286

### 287 **Cut-off Values**

288

289 DIAGNOdent measurements were categorized using validated cut-off  
290 values for smooth enamel surfaces. Values between 0-12 were classified  
291 as sound enamel, scores of 13-24 indicated initial demineralization, and  
292 readings  $\geq 25$  represented advanced demineralization[18]. These  
293 thresholds were selected based on their established validity for detecting  
294 early carious lesions on smooth surfaces.

295

**296 Data Collection**

297

**298 Clinical Parameters**

299

300 Several clinical parameters were documented at baseline to characterize  
301 the sample and ensure group comparability. These included plaque index  
302 scores to assess oral hygiene status, gingival index measurements to  
303 evaluate periodontal health, decayed-missing-filled teeth (DMFT) scores  
304 to quantify caries experience, and the duration of clear aligner treatment  
305 to account for exposure time. All clinical parameters were collected by  
306 calibrated examiners using standardized protocols.

307

**308 Behavioral Factors**

309

310 Participant behavioral factors related to oral hygiene and dietary habits  
311 were assessed through structured questionnaires. These included daily  
312 tooth brushing frequency, flossing habits, frequency of sugary food and  
313 beverage consumption, and adherence to professional oral hygiene  
314 recommendations. Behavioral data were collected to identify potential  
315 confounding factors that might influence demineralization outcomes  
316 independent of the assigned remineralization protocol.

317

318 Compliance with the assigned home-applied remineralization protocols  
319 (Groups B and C) was assessed using patient self-report diaries.

320 Participants recorded the daily application of their assigned agents.  
321 These diaries were reviewed by the examiner at each monthly follow-up  
322 visit, and compliance was calculated as (total days applied/total days in  
323 the period)  $\times$  100. Compliance for Group D was considered 100%, as the  
324 agent was professionally applied at all scheduled follow-up visits.

325

### 326 **Statistical Analysis**

327

328 As multiple teeth were obtained from each participant and repeated  
329 measurements were taken from each tooth at four different time points,  
330 the data had a hierarchical and repeated-measures structure. Therefore,  
331 a linear mixed-effects model (LMM) was used to account for within-  
332 subject and within-tooth correlations[19]. In the model, time was treated  
333 as a repeated factor and the teeth were specified as nested within the  
334 subjects. Random intercepts were included for both the subjects and  
335 teeth to allow for individual variability at each level. Fixed effects  
336 included group, time, age, gender and number of attachments. A diagonal  
337 covariance structure was applied to model the correlations among  
338 repeated observations over time. The model parameters were estimated  
339 using the Restricted Maximum Likelihood (REML) method. The  
340 significance of the fixed effects was assessed using Type III F-tests. When  
341 a significant interaction was detected, the estimated marginal means  
342 (EMMEANS) and pairwise comparisons were used to examine differences  
343 between groups across time points. A p-value  $< 0.05$  was considered  
344 statistically significant.

345 Post-hoc power analysis was performed using G\*Power 3.1 [20] to  
346 evaluate the study's power given the observed effect size (partial  $\eta^2 =$   
347 0.974).

348 During the preparation of this manuscript, the authors used AI language  
349 models (Google Gemini and ChatGPT) for language enhancement  
350 (grammar, syntax, and clarity) and formatting assistance. The authors  
351 have reviewed and edited the output and take full responsibility for the  
352 content of this publication.

353

354

### 355 **3.Results**

356

#### 357 **Participant Demographics**

358

359 Of the 52 patients screened, 7 were excluded and 45 consented to  
360 participate. Five pre-baseline withdrawals occurred: two from the CPP-  
361 ACP group (product taste intolerance with nausea and dairy allergy  
362 concerns), one from the nHAp group (city relocation), and two from the  
363 fluoride varnish group (both citing the inability to attend regular clinical  
364 appointments). The control group had no withdrawal. The final cohort of  
365 40 patients who initiated baseline measurements demonstrated 100%  
366 retention at the 6-month follow-up. This per-protocol population  
367 comprised 60% females, mean age  $22.9 \pm 7.0$  years (range: 16-45).  
368 Dropout rates were not significantly different between the initial  
369 allocation groups (Fisher's Exact Test,  $p=0.382$ ). (Figure 1)

370

**371 Missing Data**

372

373 All 40 participants who initiated the study protocol completed the 6-  
374 month follow-up, resulting in a 0% post-baseline dropout rate. Therefore,  
375 no participant-level missing-data imputation was required for the primary  
376 analysis population (n=40).

377

378 Site-level exclusions (i.e., DIAGNOdent measurements not obtained on  
379 teeth without attachments or on absent teeth) were by design and did not  
380 represent missing data requiring imputation. Of the theoretical maximum  
381 of 4480 potential measurement sites (40 patients × 28 teeth × 4 time  
382 points), 2751 (61.4%) corresponded to existing teeth with attachments  
383 and were included in the site-level dataset analysis informing the LMM.

384

385 The primary outcome was the change in DIAGNOdent scores from  
386 baseline (T0) to 6 months (T3). Secondary outcomes included the  
387 comparison of treatment efficacy among the three active interventions  
388 and assessment of temporal patterns in demineralization changes across  
389 measurement time points.

390

**391 Baseline Characteristics (Table 1)**

392

393 At baseline (T0), mean DIAGNOdent values ranged from  $10.44 \pm 2.46$   
394 (Group A) to  $12.34 \pm 1.48$  (Group B). One-way ANOVA revealed no

395 significant between-group differences in baseline DIAGNOdent scores  
396 ( $F(3,36) = 1.85, p = 0.48$ ), confirming a comparable initial enamel status  
397 across all groups (Table 1). The mean number of attachments differed  
398 significantly between groups, with Group C having more attachments  
399 ( $18.9 \pm 2.4$ ) than the other groups ( $16.1-17.3; p = 0.007$ ). Table 2 shows  
400 all timepoint values, and Figure 2 depicts the temporal trends.

401

### 402 **Primary Outcome Analysis**

403

404 The primary analysis using a linear mixed-effects model (LMM), adjusting  
405 for baseline attachment number as a covariate, revealed a highly  
406 significant main effect of GROUP on the change in DIAGNOdent scores  
407 from baseline to 6 months ( $F[3, 35] = 438.4, p < 0.001$ ). The effect size  
408 was exceptionally large (partial  $\eta^2 = 0.974$ ). The covariate baseline  
409 attachment number was not significantly associated with the outcome ( $p$   
410  $= 0.470$ ). The distribution of these changes is illustrated in Figure 3.

411

### 412 **Pairwise Comparisons**

413

414 Post-hoc pairwise comparisons with Bonferroni correction confirmed that  
415 all active treatment groups (B, C, and D) showed significantly greater  
416 reduction in DIAGNOdent scores than the control group (A) ( $p < 0.001$   
417 for all). In contrast, the control group (Group A) showed significant  
418 worsening with a mean increase of  $+4.35$  in DIAGNOdent scores ( $p <$   
419  $0.001$ ), confirming the risk of attachment-associated demineralization

420 without preventive intervention. Crucially, the nHAp group (C)  
421 demonstrated a significantly greater reduction compared to both the  
422 CPP-ACP group (B) (Mean Difference = -1.34 units,  $p < 0.001$ ) and the  
423 fluoride group (D) (Mean Difference = -0.91 units,  $p = 0.019$ ). No  
424 significant difference was found between the CPP-ACP (B) and fluoride  
425 (D) groups (Mean Difference = -0.43 units,  $p = 0.375$ ).

426

### 427 **Temporal Patterns**

428

429 Analysis of temporal patterns revealed distinct trajectories across the  
430 measurement intervals. Groups B (CPP-ACP) and C (nHAP) demonstrated  
431 progressive, monotonic reductions at each timepoint, indicating  
432 consistent remineralization throughout the study period. Group D  
433 (Fluoride) exhibited a biphasic response pattern with initial reduction  
434 from baseline to T1 (12.08→9.74), followed by a transient increase from  
435 T1 to T2 (9.74→10.83), and subsequent final reduction from T2 to T3  
436 (10.83→7.63), suggesting an initial adjustment phase before sustained  
437 remineralization. In contrast, Group A (Control) showed progressive  
438 increases in DIAGNOdent scores throughout the study period, confirming  
439 continuous demineralization without intervention. The individual patient  
440 trajectories are shown in Figure 4.

441

### 442 **Subgroup Analyses**

443

444 **Age-based Analysis:** The age cutoff of 18 years was selected to  
445 differentiate between adolescent patients, who are typically in the active  
446 growth phase and may have different compliance levels compared to  
447 adults[4, 21]. Additionally, recent studies have specifically highlighted  
448 unique risk factors for white spot lesions in adolescent patients  
449 undergoing clear aligner therapy[5]. Age-based subgroups (<18 vs. ≥18  
450 years) showed similar treatment responses ( $p(\text{interaction}) = 0.84$ ). All  
451 agents were effective regardless of the age category.

452

453 **Tooth-Type Analysis:** Posterior teeth exhibited a slightly higher mean  
454 recovery than anterior teeth (-6.1 vs -4.6 units,  $p = 0.02$ ), which was most  
455 pronounced in the nHAp and fluoride groups.

456

#### 457 **Adverse Events**

458

459 No adverse effects, including tooth hypersensitivity, gingival irritation, or  
460 enamel discoloration, were reported during the 6-month observation  
461 period. Self-reported compliance for home-applied agents (Groups B and  
462 C) exceeded 95% based on diary reviews. All participants in Group D  
463 completed their scheduled professional applications. All remineralization  
464 protocols were well tolerated.

465

#### 466 **4. Discussion**

467

468 This prospective controlled clinical trial rejected the null hypothesis,  
469 demonstrating significant differences among remineralization protocols  
470 in preventing attachment-associated demineralization during clear  
471 aligner therapy ( $p < 0.001$ ,  $\eta^2p = 0.974$ ).

472

473 This study provides the first quantitative assessment of remineralization  
474 agent effectiveness, specifically around clear aligner attachments,  
475 addressing a critical gap in the orthodontic literature. Our findings  
476 demonstrate that all three remineralization protocols—nHAp, fluoride  
477 varnish, and CPP-ACP—significantly reduced enamel demineralization  
478 compared to standard fluoride toothpaste alone, with nHAp showing the  
479 greatest effect (5.36 unit reduction in DIAGNOdent values).

480

481 The 42% increase in DIAGNOdent values observed in the control group  
482 over 6 months aligns with Liu et al.'s finding that anterior attachments  
483 represent an independent risk factor for WSL development  
484 ( $OR=2.192$ )[5]. This deterioration, despite standard fluoride toothpaste  
485 use, underscores the inadequacy of conventional oral hygiene alone in  
486 preventing attachment-associated demineralization. The attachment-  
487 enamel interface creates a unique microenvironment that facilitates  
488 biofilm accumulation and acid retention, explaining the progressive  
489 demineralization observed[5].

490

491 Our finding that nHAp demonstrated superior efficacy (-5.36 units)  
492 compared to both CPP-ACP (-4.02 units) and fluoride varnish (-4.45 units)

493 contrasts with El Mansy et al.'s hierarchy of post-orthodontic WSLs,  
494 where the difference between agents was less pronounced[15]. This  
495 discrepancy may reflect the specific challenges of the attachment  
496 environment, where the biomimetic properties of nHAp and its ability to  
497 directly integrate with the enamel structure provide particular  
498 advantages. Nano-sized particles (20-80 nm) can penetrate the  
499 microscopic irregularities at the attachment-enamel interface more  
500 effectively [22].

501  
502 The biphasic response pattern observed in the fluoride varnish group—  
503 initial improvement (T0→T1), transient worsening (T1→T2), and final  
504 improvement (T2→T3)—aligns with the established fluoride release  
505 kinetics. Recent systematic reviews have confirmed that fluoride release  
506 from varnishes typically follows a biphasic pattern that begins with a  
507 short-term peak in fluoride availability, after which levels gradually  
508 decrease[23]. This fluctuation likely reflects the specific release kinetics  
509 of fluoride varnishes, characterized by an initial 'burst effect' of high ion  
510 release followed by a rapid decline[24]. Unlike smooth surfaces, the  
511 irregular topography of attachment margins may compromise the  
512 retention of the varnish layer, causing the fluoride reservoir to deplete  
513 before the 3-month mark. The re-application of varnish at the 3-month  
514 visit (T2) likely replenished this reservoir, explaining the subsequent  
515 improvement observed at the 6-month endpoint[25]. This suggests that  
516 quarterly applications may require more frequent applications for high-  
517 risk attachment environments.

518

519 The consistent progressive improvement observed with daily home-  
520 applied agents (nHAp and CPP-ACP) supports the importance of  
521 continuous remineralization therapy. This effect was likely enhanced by  
522 the methodology of using the aligners themselves as delivery trays. This  
523 specific mode of application—using aligners as carriers—ensures  
524 prolonged contact time at the peri-attachment site, a finding supported  
525 by a recent RCT that also utilized tray-based delivery of an F-ACP mousse  
526 to successfully manage post-orthodontic WSLs[7]. Unlike episodic high-  
527 concentration exposure from professional varnish, these agents maintain  
528 steady-state mineral supersaturation in the peri-attachment environment.  
529 The superior performance of nano-hydroxyapatite may be attributed to its  
530 dual remineralization mechanism, functioning both as a source of calcium  
531 and phosphate ions and as a template that promotes epitaxial crystal  
532 growth on demineralized enamel surfaces[26, 27].

533

534 Our results demonstrated greater effect sizes ( $\eta^2=0.974$ ) than those  
535 typically reported in fixed appliance studies, wherein fluoride varnish  
536 reduces WSL incidence by approximately 36% [28]. This difference may  
537 reflect several factors. First, the removable nature of aligners allows  
538 better agent delivery during tray wear, as patients can apply  
539 remineralization agents directly to tooth surfaces before aligner  
540 insertion. Second, attachment surfaces are more accessible than bracket-  
541 adjacent enamel, facilitating more thorough cleaning and agent  
542 application. Third, our quantitative DIAGNOdent monitoring may detect

543 subtle changes missed by visual assessment methods commonly used in  
544 fixed appliance studies, potentially capturing early remineralization  
545 effects that would otherwise go unnoticed.

546

547 The 100% post-baseline retention rate in our study, while remarkable,  
548 likely reflects the motivated patient population seeking clear aligner  
549 therapy and the noninvasive nature of the interventions. Notably, all five  
550 withdrawals occurred before baseline measurements, primarily because  
551 of product intolerance or scheduling conflicts, emphasizing the  
552 importance of trial applications and thorough informed consent  
553 processes. This contrasts with fixed-appliance cohorts, where  
554 discontinuation rates are typically around 8-10% in NHS datasets, with  
555 ~4-15% reported across European studies (occasionally up to ~20%  
556 depending on the setting)[29-31].

557

558 The DIAGNOdent cut-off values used (0-12: sound, 13-24: initial  
559 demineralization,  $\geq 25$ : advanced) align with Kim et al.'s validated  
560 thresholds for smooth surfaces[18, 32]. The mean baseline values (10.4-  
561 12.3) indicated that most patients began with sound enamel or borderline  
562 demineralization, suggesting that attachment placement itself may  
563 initiate subclinical changes detectable only through quantitative methods.

564

565 The economic implications merit further consideration. Professionally  
566 applied fluoride varnish, typically delivered every 3-6 months per ADA  
567 recommendations, costs approximately US \$20-50 per application[33]. In

568 contrast, CPP-ACP creams (e.g., GC Tooth Mousse / MI Paste) and n-HAp  
569 toothpastes (e.g., Boka, RiseWell) represent modest home-care expenses,  
570 averaging US \$10–30 per month[34]. Preventing even a single cavitated  
571 lesion can offset a restorative expense averaging  $\approx$  US \$200 per tooth,  
572 highlighting the preventive value of remineralization protocols[35].

573

574 Several limitations of this study warrant discussion. First, the non-  
575 randomized allocation based on patient preference introduces potential  
576 selection bias, although the baseline characteristics were well balanced  
577 between the groups. Patients who chose active interventions may have  
578 been more motivated to maintain oral hygiene. Second, the  
579 primary limitation of this study is the small convenience sample (n=10  
580 per group) without formal a priori sample size calculation. Conventional  
581 power analysis using standard effect sizes (Cohen's  $f=0.40$ ) would have  
582 required approximately 19 participants per group for 80% power,  
583 suggesting that our study was initially underpowered[36]. However, post-  
584 hoc power analysis using G\*Power 3.1[20] revealed that the exceptionally  
585 large effect size observed (partial  $\eta^2 = 0.974$ ) yielded statistical power  
586 exceeding 0.99, indicating that the study was adequately powered to  
587 detect substantial treatment differences despite the small sample size per  
588 group. Nevertheless, this exploratory finding requires confirmation in  
589 larger, adequately powered trials with pre-specified sample size  
590 calculations. Although the high effect size compensates for the small  
591 sample size statistically, the generalizability of these findings to broader  
592 populations with different oral hygiene habits, socioeconomic

593 backgrounds, or geographic regions remains to be confirmed in larger  
594 multi-center trials. The exploratory nature of this pilot study necessitates  
595 cautious interpretation. Third, the single-center design of a university  
596 setting may not reflect community practice patterns.

597

598 The lack of blinding, inherent to the nature of the intervention, could  
599 introduce performance and detection bias. However, DIAGNOdent  
600 provides objective quantitative measurements that are less susceptible to  
601 examiner bias than are visual scoring systems. The single-examiner  
602 protocol, while ensuring consistency (ICC=0.85), limits the external  
603 validity assessment. While the normality assumption for the residuals was  
604 generally not met, the robustness of the LMM to such deviations,  
605 combined with the confirmation of variance homogeneity (Levene's test,  
606  $p=0.896$ ), supports the validity of the analysis.

607

608 Although a significant difference in baseline attachment numbers  
609 ( $p=0.007$ ) was noted between the groups, our primary linear mixed-  
610 effects model analysis was adjusted for this variable as a covariate. The  
611 analysis confirmed that baseline attachment number did not significantly  
612 influence the primary outcome ( $p=0.470$ ), indicating that the observed  
613 group differences were robust to this initial imbalance. Additionally,  
614 Group C received both professional in-office nHAp applications (ProOffice  
615 gel at T0, T1, T2) and daily home-applied nHAp gel (Nanocare),  
616 representing a more intensive protocol than the other groups. These  
617 factors should be considered when interpreting Group C's superior

618 outcomes. Future studies should stratify randomization by attachment  
619 number and standardize dosing protocols.

620

621 Strengths include the prospective design, complete follow-up, validated  
622 measurement protocol, and focus on a clinically relevant, but  
623 understudied population. The 6-month duration captures the medium-  
624 term effects relevant to typical clear aligner treatment phases. The use of  
625 commercially available products has enhanced their immediate clinical  
626 applicability.

627

628 Our findings raise several research questions: First, would more frequent  
629 fluoride varnish application (monthly or bimonthly) eliminate the biphasic  
630 pattern? Second, would combining agents (e.g., daily nHAp plus quarterly  
631 fluoride varnish) provide synergistic effects? Third, can baseline  
632 DIAGNOdent values predict individual responses to specific agents  
633 enabling personalized prevention protocols?

634

635 Long-term studies should assess whether early intervention prevents  
636 cavitation that requires restorative treatment. Microbiological  
637 assessments could elucidate whether remineralization agents also modify  
638 the composition and metabolic activity of cariogenic biofilms[37, 38].

639 Regarding clinical significance, the reduction of approximately 5

640 DIAGNOdent units observed in the nHAp group represents a meaningful  
641 shift in enamel quality. A strong positive correlation ( $r=0.892$ ) between  
642 DIAGNOdent readings and ICDAS-II scores has been demonstrated for

643 smooth surface lesions [39]. According to validated thresholds where  
644 values <13 indicate sound enamel, the observed reduction from baseline  
645 (12.1) to final (6.7) signifies a decisive transition from borderline  
646 demineralization back to the 'sound' category. This quantitative  
647 improvement corresponds to a clinically visible arrest of white spot lesion  
648 progression, equating to a shift from ICDAS code 1-2 (initial lesion) to  
649 ICDAS 0 (sound surface)[39,40]. Economic analyses comparing  
650 preventive agent costs against potential restoration expenses would  
651 inform healthcare policies.

652

## 653 **5. Conclusions**

654

655 This prospective study provides critical evidence highlighting the  
656 significant iatrogenic risk associated with untreated clear aligner  
657 attachment sites, demonstrating a substantial increase in  
658 demineralization over 6 months despite standard fluoride toothpaste use.  
659 However, our findings offer clear solutions; targeted active  
660 remineralization protocols can effectively mitigate this complication.  
661 Among the tested regimens, the intensive nano-hydroxyapatite protocol  
662 (5% professional application plus 1% daily home use) demonstrated  
663 superior efficacy, yielding a covariate-adjusted reduction of 5.36 units,  
664 which was significantly greater than that of both CPP-ACP and quarterly  
665 fluoride varnish. Although the fluctuation observed in the quarterly  
666 fluoride varnish group requires further study, all active protocols  
667 significantly outperformed the control.

668

669 These findings challenge the paradigm of passive monitoring, which is  
670 often employed in clear aligner therapy. Rather than accepting WSLs as  
671 an inevitable side effect, our data strongly support the implementation of  
672 active prevention strategies from the initiation of treatment, particularly  
673 in patients with multiple attachments. The observed DIAGNOdent  
674 reductions, particularly with the nHAp protocol, likely correspond to the  
675 shifting enamel status from 'initial demineralization' towards 'sound  
676 enamel' classifications, underscoring the clinical relevance of early  
677 intervention. For immediate clinical application, practitioners should  
678 consider risk stratification (e.g., attachment number) and patient  
679 compliance potential when selecting a remineralization protocol utilizing  
680 quantitative monitoring such as DIAGNOdent to guide interventions.

681

682 While the exploratory nature, non-randomized design, and small sample  
683 size of this pilot study necessitate cautious interpretation, the remarkably  
684 large effect size (partial  $\eta^2 = 0.974$ ) and 100% post-baseline retention  
685 rate provided compelling preliminary evidence. This study represents the  
686 first step towards personalized preventive orthodontics, where risk  
687 assessment, real-time monitoring, and targeted interventions can  
688 potentially eliminate iatrogenic WSLs. Larger, adequately powered  
689 randomized controlled trials with extended follow-up are warranted to  
690 confirm these findings, establish the minimal clinically important  
691 difference (MCID, the smallest change considered clinically meaningful)  
692 for DIAGNOdent changes, and update clinical guidelines for preventing

693 attachment-associated enamel demineralization in the rapidly growing  
694 clear aligner patient population.

695

## 696 **List of Abbreviations**

697

698 AIC: Akaike Information Criterion

699 ANOVA: Analysis of variance

700 BIC: Bayesian Information Criterion

701 CI: Confidence interval

702 CPP-ACP: Casein phosphopeptide-amorphous calcium phosphate

703 ICC: Intraclass correlation coefficient

704 LMM: Linear mixed-effects model

705 MCID: Minimal clinically important difference

706 nHAp: Nano-hydroxyapatite

707 OR: Odds ratio

708 REML: Restricted maximum likelihood

709 SD: Standard deviation

710 T0: Baseline (initial measurement)

711 T1: First follow-up (1 month)

712 T2: Second follow-up (3 months)

713 T3: Third follow-up (6 months)

714 WSL: White spot lesions

715

## 716 **Declarations**

717

718 ***Ethics approval and consent to participate***

719 This study was conducted in full accordance with the Declaration of  
720 Helsinki. This study was approved by the Bezmialem Vakif University  
721 Clinical Research Ethics Committee (Protocol No: 09/15, date:  
722 22/05/2024). All participants provided written informed consent. For  
723 participants aged 16–18 years, informed consent to participate was  
724 obtained from their parents or legal guardians in addition to the  
725 participants' assent.

726

727 ***Consent for publication***

728 Not applicable.

729

730 ***Availability of data and materials***

731 The datasets generated and analyzed during the current study are  
732 available from the corresponding author, Banu Kılıç  
733 (bkilic@bezmialem.edu.tr), on reasonable request.

734 ***Competing interests***

735 The authors declare that they have no competing interests.

736

737 ***Funding***

738 This research received no specific grant from any funding agency in the  
739 public, commercial, or not-for-profit sectors.

740 ***Authors' contributions***

741 HYU conceptualized the study, curated data, performed the investigation  
742 and measurements, and wrote the original draft. BK provided

743 supervision, project administration, methodology, and contributed to  
744 writing, review, and editing. ED provided formal analysis and  
745 methodology support, validated the statistical approach, and contributed  
746 to writing, review, and editing. All authors read and approved the final  
747 manuscript.

#### 748 ***Acknowledgements***

749 Not applicable.

750

751

752

753

754

755

756

757

758

#### 759 **REFERENCES**

760

- 761 1. Migliorati M, Isaia L, Cassaro A, Rivetti A, Silvestrini-Biavati F,  
762 Gastaldo L, Piccardo I, Dalessandri D, Silvestrini-Biavati A: Efficacy  
763 of professional hygiene and prophylaxis on preventing plaque  
764 increase in orthodontic patients with multibracket appliances: a  
765 systematic review. *Eur J Orthod* 2015, 37(3):297-307.
- 766 2. Raghavan S, Abu Alhaija ES, Duggal MS, Narasimhan S, Al-Maweri  
767 SA: White spot lesions, plaque accumulation and salivary caries-  
768 associated bacteria in clear aligners compared to fixed orthodontic

- 769 treatment. A systematic review and meta- analysis. *BMC Oral*  
770 *Health* 2023, 23(1):599.
- 771 3. Lopes PC, Carvalho T, Gomes A, Veiga N, Blanco L, Correia MJ,  
772 Mello-Moura ACV: White spot lesions: diagnosis and treatment - a  
773 systematic review. *BMC Oral Health* 2024, 24(1):58.
- 774 4. Chapman JA, Roberts WE, Eckert GJ, Kula KS, González-Cabezas C:  
775 Risk factors for incidence and severity of white spot lesions during  
776 treatment with fixed orthodontic appliances. *Am J Orthod*  
777 *Dentofacial Orthop* 2010, 138(2):188-194.
- 778 5. Liu Q, Song Z: Incidence, severity, and risk factors for white spot  
779 lesions in adolescent patients treated with clear aligners. *Orthod*  
780 *Craniofac Res* 2024, 27(5):704-713.
- 781 6. AlignTechnology: Align Technology Among Top 300 Worldwide  
782 Organizations Granted U.S. Patents in 2023 [www.aligntech.com](http://www.aligntech.com).  
783 In.; 2024.
- 784 7. Ciribè M, Cirillo E, Mammone M, Vallogini G, Festa P, Piga S,  
785 Ferrazzano GF, Galeotti A: Efficacy of F-ACP-Containing Dental  
786 Mousse in the Remineralization of White Spot Lesions after Fixed  
787 Orthodontic Therapy: A Randomized Clinical Trial. *Biomedicines*  
788 2024, 12(6).
- 789 8. Bisht S, Khera AK, Raghav P: White spot lesions during orthodontic  
790 clear aligner therapy: A scoping review. *J Orthod Sci* 2022, 11:9.
- 791 9. Toodehzaeim MH, Rezaie N: Effect of Saliva Contamination on  
792 Microleakage Beneath Bonded Brackets: A Comparison Between

- 793 Two Moisture-Tolerant Bonding Systems. *J Dent (Tehran)* 2015,  
794 12(10):747-755.
- 795 10. Sim D, Farella M: Methodological issues in current clear aligner  
796 research. *Seminars in Orthodontics* 2025.
- 797 11. Knösel M, Vogel Alvarez R, Blanck-Lubarsch M, Helms HJ:  
798 Comparison of potential long-term costs for preventive dentistry  
799 treatment of post-orthodontic labial versus lingual enamel  
800 cavitations and esthetically relevant white-spot lesions: a simulation  
801 study with different scenarios. *Head Face Med* 2019, 15(1):22.
- 802 12. Listl S, Galloway J, Mossey PA, Marcenes W: Global Economic  
803 Impact of Dental Diseases. *J Dent Res* 2015, 94(10):1355-1361.
- 804 13. Baccolini V, da Silva LP, Teixeira L, de Sousa RT, Manarte-Monteiro  
805 P: The Role of Casein Phosphopeptide-Amorphous Calcium  
806 Phosphate (CPP-ACP) in White Spot Lesion Remineralization—A  
807 Systematic Review. *Journal of Functional Biomaterials* 2025,  
808 16(8):272.
- 809 14. Alajlan S, A B: The effect of nano-hydroxyapatite on white spot  
810 lesions: A systematic review and meta-analysis. *J Dent* 2024,  
811 151:105402.
- 812 15. El Mansy MM, Rashed MF, Saleh RS: Effect of remineralization  
813 after in office followed by home treatment of white spot lesions in  
814 children randomized controlled trial. *Scientific Reports* 2025,  
815 15(1):30448.
- 816 16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC,  
817 Vandembroucke JP: The Strengthening the Reporting of

- 818 Observational Studies in Epidemiology (STROBE) statement:  
819 guidelines for reporting observational studies. *J Clin Epidemiol*  
820 2008, 61(4):344-349.
- 821 17. Alhamed M, Almalki F, Alselami A, Alotaibi T, Elkwatehy W: Effect  
822 of different remineralizing agents on the initial carious lesions - A  
823 comparative study. *Saudi Dent J* 2020, 32(8):390-395.
- 824 18. KaVo Dental GmbH.: KaVo DIAGNOdent pen 2190. Instructions for  
825 use. In. Biberach, Germany; 2020.
- 826 19. Montesinos López OA, Montesinos López A, Crossa J: Linear Mixed  
827 Models. In: *Multivariate Statistical Machine Learning Methods for*  
828 *Genomic Prediction*. edn. Edited by Montesinos López OA,  
829 Montesinos López A, Crossa J. Cham: Springer International  
830 Publishing; 2022: 141-170.
- 831 20. Faul F, Erdfelder E, Lang AG, Buchner A: G\*Power 3: a flexible  
832 statistical power analysis program for the social, behavioral, and  
833 biomedical sciences. *Behav Res Methods* 2007, 39(2):175-191.
- 834 21. Barbosa IV, Ladewig VM, Almeida-Pedrin RR, Cardoso MA,  
835 Santiago Junior JF, Conti A: The association between patient's  
836 compliance and age with the bonding failure of orthodontic  
837 brackets: a cross-sectional study. *Prog Orthod* 2018, 19(1):11.
- 838 22. Pawinska M, Paszynska E, Amaechi BT, Meyer F, Enax J, Limeback  
839 H: Clinical evidence of caries prevention by hydroxyapatite: An  
840 updated systematic review and meta-analysis. *J Dent* 2024,  
841 151:105429.

- 842 23. Dobrzyński M, Kotela A, Klimas S, Majchrzak Z, Kensy J,  
843 Laszczyńska M, Michalak M, Rybak Z, Fast M, Matys J: Evaluation  
844 of Factors Affecting Fluoride Release from Fluoride Varnishes: A  
845 Systematic Review. *Materials* 2025, 18(19):4603.
- 846 24. Lippert F: Fluoride release from fluoride varnishes under acidic  
847 conditions. *J Clin Pediatr Dent* 2014, 39(1):35-39.
- 848 25. Seppä L: Fluoride varnishes in caries prevention. *Med Princ Pract*  
849 2004, 13(6):307-311.
- 850 26. Dai D, Li D, Zhang C: Unraveling Nanomaterials in Biomimetic  
851 Mineralization of Dental Hard Tissue: Focusing on Advantages,  
852 Mechanisms, and Prospects. *Advanced Science* 2024,  
853 11(40):2405763.
- 854 27. Zhu GY, Liu YH, Liu W, Huang XQ, Zhang B, Zheng ZL, Wei X, Xu  
855 JZ, Zhao ZH: Surface Epitaxial Nano-Topography Facilitates  
856 Biomineralization to Promote Osteogenic Differentiation and  
857 Osteogenesis. *ACS Omega* 2021, 6(33):21792-21800.
- 858 28. Sonesson M, Twetman S: Prevention of white spot lesions with  
859 fluoride varnish during orthodontic treatment with fixed appliances:  
860 a systematic review. *Eur J Orthod* 2023, 45(5):485-490.
- 861 29. Price J, Whittaker W, Birch S, Brocklehurst P, Tickle M:  
862 Socioeconomic disparities in orthodontic treatment outcomes and  
863 expenditure on orthodontics in England's state-funded National  
864 Health Service: a retrospective observational study. *BMC Oral*  
865 *Health* 2017, 17(1):123.

- 866 30. Vithanaarachchi VsN, Medagama T, Nawarathna L: Assessment of  
867 contributing factors for discontinuation of orthodontic treatment.  
868 *APOS Trends in Orthodontics* 2020, 10:105-110.
- 869 31. Ahlgren J: A ten-year evaluation of the quality of orthodontic  
870 treatment. *Swed Dent J* 1993, 17(5):201-209.
- 871 32. Kim K, Jung HI, Park W, Lee KE, Kang CM, Song JS: Optimizing  
872 fluorescence-based caries detection: A diagnostic performance  
873 analysis of SmarTooth and DIAGNOdent pen. *Photodiagnosis*  
874 *Photodyn Ther* 2025, 55:104731.
- 875 33. Meadowdale Dental C: Fluoride Treatment Cost Guide 2023. 2023.
- 876 34. Corporation GC, Boka Oral C: GC Tooth Mousse / MI Paste Product  
877 Information & Boka n-HAp Toothpaste Pricing. 2024.
- 878 35. GoodRx H: Average Cost of Dental Fillings (Composite  
879 Restorations) in the United States. 2024.
- 880 36. Cohen J: Statistical Power Analysis. *Current Directions in*  
881 *Psychological Science* 1992, 1(3):98-101.
- 882 37. Han Y: Effects of brief sodium fluoride treatments on the growth of  
883 early and mature cariogenic biofilms. *Scientific Reports* 2021,  
884 11(1):18290.
- 885 38. El-Gar Y, Al-Madboly L, Etman W, Genaid T: Potent Antibacterial  
886 and Antibiofilm Activities of a Synthetic Remineralizing Preparation  
887 of Nano-Hydroxyapatite Against Cariogenic *Streptococcus mutans*  
888 Using an Ex-vivo Animal Model. *Frontiers in Dental Medicine* 2022,  
889 3.

- 890 39. Shaalan OO: DIAGNOdent versus International Caries Detection  
891 and Assessment System in detection of incipient carious lesions: A  
892 diagnostic accuracy study. *J Conserv Dent* 2023, 26(2):199-206.
- 893 40. Lussi A, Hellwig E: Performance of a new laser fluorescence device  
894 for the detection of occlusal caries in vitro. *J Dent* 2006, 34(7):467-  
895 471.
- 896
- 897

ARTICLE IN PRESS

898 **Table 1. Demographics and Baseline Characteristics of Study**899 **Participants**

Characteristic	Group				Total	p-value
	Group A (Control)	Group B (CPP-ACP)	Group C (nHAp)	Group D (Fluoride)		
n	10	10	10	10	40	-
Age (years), Mean $\pm$ SD	22.6 $\pm$ 6.7	22.5 $\pm$ 6.0	23.8 $\pm$ 8.5	22.7 $\pm$ 6.6	22.9 $\pm$ 7.0	0.92†
Range	16-38	16-35	16-45	16-36	16-45	
Sex, n (%) Female	6 (60.0)	5 (50.0)	6 (60.0)	7 (70.0)	24 (60.0)	0.68‡
Male	4 (40.0)	5 (50.0)	4 (40.0)	3 (30.0)	16 (40.0)	
Baseline DIAGNOdent, Mean $\pm$ SD	10.4 $\pm$ 2.5	12.3 $\pm$ 1.5	12.1 $\pm$ 0.7	12.1 $\pm$ 0.9	11.5 $\pm$ 1.6	0.48†
Median (IQR)	9.5 (7.0-12.0)	11.0 (9.0-15.0)	11.0 (8.0-15.0)	11.0 (8.5-14.5)	10.5 (8.0-14.0)	
DIAGNOdent Category, n (%) Sound (0-12)	7 (70.0)	5 (50.0)	5 (50.0)	5 (50.0)	22 (55.0)	0.76‡

Characteristic	Group				Total	p-value
	Group A (Control)	Group B (CPP-ACP)	Group C (nHAp)	Group D (Fluoride)		
Initial (13-24)	3 (30.0)	4 (40.0)	4 (40.0)	4 (40.0)	15 (37.5)	
Advanced ( $\geq 25$ )	0 (0.0)	1 (10.0)	1 (10.0)	1 (10.0)	3 (7.5)	
<b>Initial enrollment (n)</b>	10	12	11	12	-	-
<b>Dropout rate (%)<sup>1</sup></b>	0%	16.7%	9.1%	16.6%		0.382 <sup>2</sup>

900 **Abbreviations:** CPP-ACP, casein phosphopeptide-amorphous calcium  
 901 phosphate; nHAp, nano-hydroxyapatite; SD, standard deviation; IQR,  
 902 interquartile range.

903 † One-way ANOVA.

904 ‡ Chi-square test.

905 <sup>1</sup> Percentage based on initial enrollment numbers before pre-baseline  
 906 withdrawals.

907 <sup>2</sup> Fisher's Exact Test comparing dropout rates between initial allocation  
 908 groups.

909 **Note:** No significant differences were observed between groups for  
 910 baseline age, sex, or DIAGNOdent score (all  $p > 0.05$ ). Group D received  
 911 ProShield varnish (PRESIDENT DENTAL GmbH, Allershausen, Germany)  
 912 as the fluoride intervention.

913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926

**Table 2. DIAGNOdent values at each timepoint by treatment group showing temporal changes from baseline (T0) to 6 months (T3)**

Group	Baseline	1 Month	3 Months	6 Months	$\Delta$ (T3 -	<i>p</i> -value
	(T0) Mean $\pm$ SD [95% CI]	(T1) Mean $\pm$ SD [95% CI]	(T2) Mean $\pm$ SD [95% CI]	(T3) Mean $\pm$ SD [95% CI]	T0) Mean [95% CI]	
<b>Control (A)</b>	10.4 $\pm$ 2.5 [8.7-12.2]	11.5 $\pm$ 2.5 [9.7-13.2]	12.2 $\pm$ 2.6 [10.3-14.1]	14.8 $\pm$ 2.6 [13.0-16.6]	+4.35 [3.77-4.93]	< 0.001

Group	Baseline (T0) Mean ± SD [95% CI]	1 Month	3 Months	6 Months	Δ (T3 –	<i>p</i> - value †
		(T1) Mean ± SD [95% CI]	(T2) Mean ± SD [95% CI]	(T3) Mean ± SD [95% CI]	T0) Mean [95% CI]	
<b>CPP- ACP (B)</b>	12.3 ± 1.5 [11.3-13.4]	11.1 ±	9.9 ± 1.3	8.3 ± 1.2	-4.02	< 0.001
		1.6 [10.0- 12.3]	[9.0-10.8]	[7.4-9.2]	[-4.47 to -3.56]	
<b>nHAp (C)</b>	12.1 ± 0.7 [11.6-12.6]	10.0 ±	8.8 ± 0.7	6.7 ± 0.6	-5.36	< 0.001
		0.9 [9.3- 10.6]	[8.2-9.3]	[6.2-7.1]	[-5.99 to -4.72]	
<b>Fluoride (D)</b>	12.1 ± 0.9 [11.5-12.7]	9.7 ± 1.1	10.8 ± 1.0	7.6 ± 0.8	-4.45	< 0.001
		[9.0-10.5]	[10.1-11.6]	[7.0-8.1]	[-4.78 to -4.11]	

927

928

929

930

931

932

933

934

935 **Figure Legends**

936

937 **Figure 1.** STROBE flow diagram of participant enrollment, allocation,  
938 and follow-up. The study assessed 52 patients for eligibility, excluded 7  
939 based on predefined criteria, and enrolled 45 participants. Following  
940 allocation by patient preference and 5 pre-baseline withdrawals, 40  
941 participants (10 per group) initiated baseline measurements. All  
942 participants completed the 6-month follow-up (100% post-baseline  
943 retention) and were included in the per-protocol analysis. A total of 2,751  
944 attachment sites were measured.

945

946 **Figure 2.** Temporal changes in DIAGNOdent values (mean  $\pm$  SD) across  
947 four treatment groups over 6 months. Shaded areas represent clinical  
948 thresholds: green (0-12) indicates sound enamel, yellow (12-24) indicates  
949 initial demineralization. The dashed line at 12 marks the transition  
950 threshold. Note the biphasic response pattern in the fluoride varnish  
951 group at 3 months. Error bars represent standard deviation; n=10 per  
952 group.

953

954 **Figure 3.** Box plots showing change in DIAGNOdent values from baseline  
955 to 6 months (T3-T0). Negative values indicate remineralization; positive  
956 values indicate demineralization. The dashed line at y=0 represents no  
957 change. Boxes show IQR with median line; whiskers extend to min/max  
958 values; circles indicate outliers. Significance: \*\*\*p<0.001, \*p<0.05. The

959 nHAp group demonstrated the greatest reduction, significantly  
960 outperforming both CPP-ACP ( $p<0.001$ ) and fluoride varnish ( $p=0.019$ ).

961  
962 **Figure 4.** Individual patient trajectories (spaghetti plots) showing  
963 DIAGNOdent values over 6 months for all study participants. Each thin  
964 colored line represents an individual patient ( $n=10$  per group); thick dark  
965 lines indicate group means. (A) Control group shows consistent  
966 deterioration across all patients. (B) CPP-ACP group demonstrates  
967 uniform improvement. (C) nHAp group exhibits the greatest and most  
968 consistent reduction. (D) Fluoride varnish group displays characteristic  
969 biphasic response pattern with temporary worsening at 3 months in most  
970 patients before final improvement.

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

ARTICLE IN PRESS

Figure 1. STROBE Flow Diagram





Figure 2. Temporal Changes in DIAGNOdent Values (Mean  $\pm$  SD)

988

989

990

991

992

993

994

995


996

997

998

999

Figure 3. Change in DIAGNOdent Values from Baseline to 6 Months



1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

Figure 4. Individual Trajectories by Group





Figure 3. Change in DIAGNOdent Values from Baseline to 6 Months




**Figure 2. Temporal Changes in DIAGNOdent Values (Mean  $\pm$  SD)**

Figure 1. STROBE Flow Diagram






Figure 4. Individual Trajectories by Group


A: Control (n=10)



B: CPP-ACP (n=10)



C: nHAp (n=10)



D: Fluoride Varnish (n=10)

